why choose us

First received: May 24, 2023

Clinical Trial: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Leukemia

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2a, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety and Efficacy of GDX012 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Brief Summary: GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML).The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and to determine the best dose of GDX012.

Read more